β2–Adrenergic Receptor Antagonism Attenuates CNV Through Inhibition of VEGF and IL-6 Expression

PURPOSE: The role of β–adrenergic receptor (AR) signaling in neovascular ocular diseases has recently emerged. We have previously reported that intraperitoneal propranolol inhibits choroidal neovascularization (CNV) in vivo and β2-AR blockade reduces vascular endothelial growth factor (VEGF) express...

Descripción completa

Detalles Bibliográficos
Autores principales: Lavine, Jeremy A., Farnoodian, Mitra, Wang, Shoujian, Darjatmoko, Soesiawati R., Wright, Lynda S., Gamm, David M., Ip, Michael S., Sorenson, Christine M., Sheibani, Nader
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Association for Research in Vision and Ophthalmology 2017
Materias:
Biochemistry and Molecular Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256681/
https://www.ncbi.nlm.nih.gov/pubmed/28114591
http://dx.doi.org/10.1167/iovs.16-20204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256681/
https://www.ncbi.nlm.nih.gov/pubmed/28114591
http://dx.doi.org/10.1167/iovs.16-20204

Ejemplares similares